Cancer Tumor Markers And Its Latest Trends

Year : 2024 | Volume : | : | Page : –
By
vector

Saksham Gupta,

  1. Student, Department of Biochemistry, Bundelkhand University, Jhansi, Uttar Pradesh, India

Abstract document.addEventListener(‘DOMContentLoaded’,function(){frmFrontForm.scrollToID(‘frm_container_abs_114043’);});Edit Abstract & Keyword

Almost one in six deaths occurs due to abnormal cell division; these cells are termed cancer cells in general. Cancer cells collaborate to multiply and metastasize. Our aim is to awaken awareness in people to understand their bodies and motivate them for early diagnosis,as cancer is the second leading cause of death after cardiovascular disease. The human body is a marvellous creation in nature; in response to cancer, it creates tumour markers. A tumor marker is a substance made by cancer cells or by the body’s cells in reaction to the presence of cancer. The purpose of this review is to give a brief overview of the clinical uses of tumor markers and to categorise the wide variety of tumor markers based on the types of cancer. Tumor markers play a pivotal role in the diagnosis, prognosis, and monitoring of various cancers, aiding in the identification and management of various cancers and addressing ethical considerations in the use of genetic markers. This review also reflects on the guidelines and general principles on cancer tumor markers and the emerging latest trends and technology. The exploration of novel tumour markers, emphasising their potential in the early detection and monitoring of ovarian cancer, shedding light on their unique attributes and implications for cancer diagnostics, and the challenge of tumor marker utilisation. The advantages and limitations inherent in the use of tumor markers, including those in common clinical practice, are critically evaluated. Tumor markers have become indispensable diagnostic tools in clinical oncology.

Keywords: Cancer, ethical considerations, emerging latest trends, pivotal role, tumour marker

How to cite this article:
Saksham Gupta. Cancer Tumor Markers And Its Latest Trends. Research & Reviews: Journal of Oncology and Hematology. 2024; ():-.
How to cite this URL:
Saksham Gupta. Cancer Tumor Markers And Its Latest Trends. Research & Reviews: Journal of Oncology and Hematology. 2024; ():-. Available from: https://journals.stmjournals.com/rrjooh/article=2024/view=0

Full Text PDF

Full Text PDF

References
document.addEventListener(‘DOMContentLoaded’,function(){frmFrontForm.scrollToID(‘frm_container_ref_114043’);});Edit

  1. NIH International Cancer Institute. “Tumor Markers: Fact Sheet.” National Cancer Institute, https://www.cancer.gov/about-cancer/diagnosis-staging/diagnosis/tumor-markers-fact-sheet.
  2. Duffy, M.J. “Clinical Uses of Tumor Markers: A Critical Review.” Ann Clin Biochem, 2008, pp. 225-262.
  3. Bhatt, A.N., Mathur, R., Farooque, A., Verma, A., Dwarakanath, B.S. “Cancer Biomarkers – Current Perspectives.” Indian J Med Res, 2010, vol. 132, pp. 129–49.
  4. Virji, M.A., Mercer, D.W., Herberman, R.B. “Tumor Markers in Cancer Diagnosis and Prognosis.” CA Cancer J Clin, 1988, vol. 38, pp. 104–26.
  5. Diamandis, E.P. “Tumor Markers: Past, Present, and Future.” Tumor Markers: Physiology, Pathobiology, Technology, and Clinical Applications, edited by E.P. Diamandis et al., AACC Press, 2002, pp. 3–8.
  6. Sokoll, L.J., Chan, D.W. “Clinical Chemistry: Tumor Markers.” Abeloff: Clinical Oncology, 3rd ed., edited by M.D. Abeloff et al., Elsevier Churchill Livingston, 2004.
  7. Schrohl, A.S., Anderson, M.H., Sweep, F., Schmitt, M., Harbeck, N., Foekens, J., et al. “Tumor Markers: From Laboratory to Clinical Utility.” Mol Cell Proteomics, 2003, vol. 2, pp. 378–87.
  8. Goedegebuure, P.S., Liyanange, U., Eberlein, T.J. “Tumor Biology and Tumor Markers.” Sabiston Textbook of Surgery, 17th ed., edited by C.M. Townsend et al., Elsevier Saunders, 2004.
  9. Hirsch, F.R., Franklin, W.A., Gazdar, A.F., Bunn, P.A. Jr. “Early Detection of Lung Cancer: Clinical Perspectives of Recent Advances in Biology and Radiology.” Clin Cancer Res, 2001, vol. 7, pp. 5–22.
  10. Miller, B.A., Kolonel, L.N., Bernstein, L., et al. “Racial/Ethnic Patterns of Cancer in the United States, 1988–1992.” US Cancer Patterns, National Cancer Institute, 1996, pub 96–4104.
  11. Garber, M.E., Troyanskaya, O.G., Schluens, K., Petersen, S., Thaesler, Z., Pacyna-Gengelbach, M., van de Rijn Matt, Rosen, G.D., Perou, C.M., Whyte, R.I. “Diversity of Gene Expression in Adenocarcinoma of the Lung.” Proc Natl Acad Sci USA, 2001, vol. 98, pp. 13784–13789.
  12. Jakupciak, P.J., Wang, W., Markowitz, M., Ally, D., Coble, M., Srivastava, M., et al. “J Mol Diagn.” 2005 May; 7(2): 258–267.
  13. Banks, E. “The Epidemiology of Ovarian Cancer.” Ovarian Cancer: Methods and Protocols, edited by J.M.S. Bartlett, Humana Press, 2000.
  14. “United States Cancer Statistics 2002 Incidence and Mortality.” National Cancer Institute, 2005, http://seer.cancer.gov/csr/1975_2006/results_single/sect_01_table.01.pdf.
  15. Urban, N., Drescher, C. “Potential and Limitations in Early Diagnosis of Ovarian Cancer.” Ovarian Cancer: State of the Art and Future Directions in Translational Research, edited by G. Coukos et al., Springer, 2008, pp. 3–14.
  16. Badgwell, D., Bast, R.C. “Early Detection of Ovarian Cancer.” Disease Markers, 2007, vol. 23(5-6), pp. 397–410
  17. Rein, Brandon J D et al. “Potential markers for detection and monitoring of ovarian cancer.” Journal of oncology vol. 2011 (2011): 475983.
  18. Hartge, P., Whittemore, A.S., Itnyre, J., McGowan, L., Cramer, D. “Rates and Risks of Ovarian Cancer in Subgroups of White Women in the United States.” Obstetrics and Gynecology, 1994, vol. 84(5), pp. 760–764.
  19. Whittemore, A.S., Harris, R., Itnyre, J., et al. “Characteristics Relating to Ovarian Cancer Risk: Collaborative Analysis of 12 US Case-Control Studies. II. Invasive Epithelial Ovarian Cancers in White Women.” *American Journal of Epidemiology*, 1992, vol. 136, no. 10, pp. 1184–1203.
  20. Beral, V., Fraser, P., Chilvers, C. “Does Pregnancy Protect Against Ovarian Cancer?” *Lancet*, 1978, vol. 1, no. 8073, pp. 1083–1087.
  21. Nagpal, M., Singh, S., Singh, P., Chauhan, P., and Abbas, Z.M. “Tumor Markers: A Diagnostic Tool.” *Nat J Maxillofac Surg*, 2016, vol. 7, no. 1, pp. 17–20.
  22. Garg, A., Ahmed, S., Sinha, A., Singh, H.P. “Tumor Markers – Its Advantages and Limitations in Diagnosis of Oral Cancer.” *Univ J Dent Sci*, 2015, vol. 1, pp. 42–45.
  23. Tumuluri, V., Thomas, G.A., Fraser, I.S. “Analysis of the Ki-67 Antigen at the Invasive Tumor Front of Human Oral Squamous Cell Carcinoma.” *J Oral Pathol Med*, 2002, vol. 31, pp. 598–604.
  24. Matsumoto, M., Komiyama, K., Okaue, M., Shimoyama, Y., Iwakami, K., Namaki, S., et al. “Predicting Tumor Metastasis in Patients with Oral Cancer by Means of the Proliferation Marker Ki67.” J Oral Sci, 1999, vol. 41, pp. 53–6.
  25. Hussain, T., Nguyen, Q.T. “Molecular Imaging for Cancer Diagnosis and Surgery.” *Adv. Drug Deliv. Rev.*, 2014, vol. 66, pp. 90.
  26. Coleman, R., Finkelstein, D.M., Barrios, C., et al. “Adjuvant Denosumab in Early Breast Cancer (D-CARE): An International, Multicentre, Randomised, Controlled, Phase 3 Trial.” *Lancet Oncol.*, 2020, vol. 21, pp. 60–72.
  27. Taouli, B., Beer, A.J., Chenevert, T., et al. “Diffusion-Weighted Imaging Outside the Brain: Consensus Statement From an ISMRM-Sponsored Workshop.” *J. Magn. Reason. Imaging*, 2016, vol. 44, pp. 521–540. .
  28. Padhani, A.R., Liu, G., Mu-Koh, D., et al. “Diffusion-Weighted Magnetic Resonance Imaging as a Cancer Biomarker: Consensus and Recommendations.” *Neoplasia*, 2009, vol. 1, pp. 102–125.
  29. Altintas, Z., Tothill, I. “Biomarkers and Biosensors for the Early Diagnosis of Lung Cancer.” Sens. Actuators B Chem, 2013, vol. 188, pp. 988–998.
  30. del Sol, A., Balling, R., Hood, L., Galas, D. “Diseases as Network Perturbations.” *Curr. Opin. Biotechnol.*, 2010, vol. 21, pp. 566–571.
Ahead of Print Subscription Review Article
Volume
Received 02/10/2024
Accepted 19/10/2024
Published 18/11/2024
260